A Phase 2, Randomized, Open-Label Study of Two Dose Levels of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer (TAMARACK)

Status

Ongoing, recruiting

Phase

Therapeutic exploratory (Phase II)

Sponsor

Macrogenics Inc.

Enrolment target

61

Start

17 Feb 2023

Age 18 Years to any · Sex: Male

• —

  Belgium
• —

  Germany
• —

  France
• —

  Italy
• —

  Poland
• —

  Spain
• —

  Czechia